Clinical trials: Essential Hypertension.
Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02483936
- Testing
- Olmesartan medoxomil 40mg + chlorthalidone 12,5mg, Olmesartan medoxomil 40mg + chlorthalidone 25mg, Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Essential Arterial Hypertension
Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
- Trial name
- NCT02493322
- Testing
- Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg, Olmesartan medoxomil 20mg + Chlortalidone 25mg, Olmesartan 20mg + hydrochlorothiazide 12,5mg
- Sponsor
- EMS
Hypertension
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus
The primary objective is to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives are the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides…
- Trial name
- NCT02242825
- Testing
- Micardis®, MicardisPlus®
- Volunteers
- 8,148 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
- Trial name
- NCT00430950
- Testing
- olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg
- Where
- 41 sites in Belgium, Germany and 2 more
- Volunteers
- 1,011 people
- Sponsor
- Daiichi Sankyo
Essential Hypertension, Chronic Stable Angina
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- NCT01819870
- Testing
- Dilatrend SR capsule 32mg, Dilatrend IR tablet 25mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension
The antihypertensive effect of Amlodipine/Valsartan combination has been evaluated in worldwide populations including Asian patients.
- Trial name
- NCT02058446
- Testing
- Amlodipine/Valsartan
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- TSH Biopharm Corporation Limited
Hypertension
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo.
- Trial name
- NCT00549770
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 182 sites in United States, Argentina and 16 more
- Volunteers
- 1,334 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.
- Trial name
- NCT02848170
- Testing
- CS-3150, olmesartan medoxomil
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Hypertension
Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
The purpose of the study is to test the efficacy and safety of the combination of Calcium Channel Blockers (CCBs)(of the dihydropyridine class) or Diuretics (of the thiazide class) and olmesartan medoxomil in essential…
- Trial name
- NCT00858702
- Testing
- olmesartan medoxomil and a CCB, olmesartan medoxomil and a diuretic
- Where
- Japan
- Volunteers
- 105 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Isolated Systolic Hypertension
SER100 in Isolated Systolic Hypertension
Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity.
- Trial name
- NCT01987284
- Testing
- SER100
- Where
- 7 sites in Finland, Hungary and 2 more
- Volunteers
- 17 people
- Sponsor
- Serodus AS
Essential Hypertension
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy
- Trial name
- NCT05475665
- Testing
- Irbesartan/Amlodipine, Irbesartan
- Where
- South Korea
- Volunteers
- 157 people
- Sponsor
- Handok Inc.
Essential Hypertension
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.
- Trial name
- NCT01256411
- Testing
- LCZ696, Amlodipine, Hydrochlorothiazide (HCTZ)
- Where
- 33 sites in China, Japan and 3 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
A multicenter, randomized, double-blind, phase III study to evaluate the efficacy and safety of HCP2102 in patients with essential hypertension
- Trial name
- NCT05450601
- Testing
- HCP2102-1, HPP2104-1, HCP2102-2
- Where
- South Korea
- Volunteers
- 249 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
High Dose BAYA1040_Nifedipine: a Long Term Combination Study
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at…
- Trial name
- NCT01294215
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 4 sites in Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Essential Hypertension
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of Early Morning Blood Pressure and Central Arterial Pressure.
- Trial name
- NCT02357615
- Testing
- nifedipine CR tablets (Xin Ran), Adalat
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
Hypertension
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment
- Trial name
- NCT02620163
- Testing
- telmisartan/amlodipine 40/5mg, YH22162 40/5/12.5 mg, telmisartan/amlodipine 80/5mg
- Where
- South Korea
- Volunteers
- 381 people
- Sponsor
- Yuhan Corporation
Hypertension
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension
- Trial name
- NCT00294710
- Testing
- Aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 976 people
- Sponsor
- Novartis
Hypertension
A Study of Controlled-Release Carvedilol Compared to Immediate-Release Carvedilol in Patients With Primary Hypertension
The purpose of this study is to compare the efficacy of the Egalet® controlled release formulation to an immediate release Carvedilol tablet.
- Trial name
- NCT00444834
- Testing
- Carvedilol
- Where
- 2 sites in Denmark
- Volunteers
- 14 people
- Sponsor
- Egalet Ltd
Mild Essential Hypertension, Moderate Essential Hypertension
Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
The study medication CYT006-AngQb is a vaccine, consisting of angiotensin II (Ang II), the naturally occurring octapeptide coupled onto the surface of virus-like particles (VLP).
- Trial name
- NCT00710372
- Testing
- CYT006-AngQb
- Where
- Switzerland
- Volunteers
- 83 people
- Sponsor
- Cytos Biotechnology AG
Hypertension
An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)
Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.
- Trial name
- NCT00449111
- Testing
- MK0954, losartan potassium / Duration of Treatment - 12 weeks
- Volunteers
- 11 people
- Sponsor
- Organon and Co